ZymoGenetics: Merck Serono Halts MS Study

Seattle biotechnology company ZymoGenetics Inc. said that Merck Serono SA had decided to halt studies of ZymoGenetics’ drug candidate atacicept for treatment of multiple sclerosis.
Puget Sound Business Journal